Clinical Trial Update: Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluating the safety and efficacy of IC19 CAR-T Cell Therapy for refractory systemic lupus erythematosus is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• IC19 CAR-T Cell Therapy

Snippet

Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd. | Conditions: Difficult to Treat Systemic Lupus Erythematosus | EARLY_Phase 1 | Status: NOT_YET_RECRUITING